{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:57:26Z","timestamp":1778637446903,"version":"3.51.4"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,4,7]]},"abstract":"<jats:p> PURPOSE: To assess the safety and efficacy of vinorelbine in patients with AIDS-related Kaposi\u2019s sarcoma (KS). <\/jats:p><jats:p> PATIENTS AND METHODS: From December 1994 to May 1997, within the Italian Cooperative Group on AIDS and Tumors, we enrolled 36 patients with AIDS-related KS who experienced disease progression after one or more regimens of systemic chemotherapy. Patients were treated with vinorelbine 30 mg\/m<jats:sup>2<\/jats:sup> every 2 weeks by intravenous bolus. <\/jats:p><jats:p> RESULTS: Of 35 assessable patients, three (9%) had a clinical complete response and 12 (34%) had a partial remission, for an overall objective response rate of 43% (95% confidence interval, 26% to 61%). For the 15 patients with objective responses, the median duration of response from the beginning of therapy until the development of progression was 176 days, whereas the median progression-free survival and the median survival durations for 35 assessable patients were 151 days and 216 days, respectively. Vinorelbine also induced responses in patients who had become resistant to regimens that included other vinca alkaloids. Overall, vinorelbine was well tolerated. Toxicity, including neurologic toxicity, was mild and reversible. Neutropenia was the most frequent dose-limiting toxicity. <\/jats:p><jats:p> CONCLUSION: Vinorelbine is safe and effective in the treatment of patients with advanced KS who have been previously treated with one or more chemotherapy regimens. <\/jats:p>","DOI":"10.1200\/jco.2000.18.7.1550","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T07:12:37Z","timestamp":1487920357000},"page":"1550-1557","source":"Crossref","is-referenced-by-count":49,"title":["Vinorelbine Is an Effective and Safe Drug for AIDS-Related Kaposi\u2019s Sarcoma: Results of a Phase II Study"],"prefix":"10.1200","volume":"18","author":[{"given":"Guglielmo","family":"Nasti","sequence":"first","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Errante","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Talamini","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Rizzardini","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fasan","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Landonio","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Zeroli","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Chichino","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezio","family":"Nigra","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Vaccher","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Tirelli","sequence":"additional","affiliation":[{"name":"From the Division of Medical Oncology A and Epidemiology UnitCentro di Riferimento Oncologico, Aviano; I and II Divisions of Infectious Diseases, Ospedale L. Sacco, Milano; Division of Medical Oncology, Ospedale Niguarda C\u00e0 Granda, Milano; Division of Infectious Diseases, Ospedale di Circolo, Varese; Institute of Infectious Diseases, Policlinico San Matteo, Pavia; and Division of Infectious Diseases B, Ospedale Amedeo di Savoia, Torino, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0188","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199714000-00010"},{"key":"R2-0188","doi-asserted-by":"crossref","unstructured":"Jacobson  LP:  Impact of highly effective anti-retroviral therapy on the incidence of malignancies among HIV-infected individuals.  J Acquir Immune Defic Syndr 17:A39,1998  (abstr)","DOI":"10.1097\/00042560-199804010-00126"},{"key":"R3-0188","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90001-L"},{"key":"R4-0188","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920050-00002"},{"key":"R5-0188","unstructured":"Kaplan  L,  Abrams  D,  Volberding  P:  Treatment of Kaposi\u2019s sarcoma in AIDS with an alternating vincristine-vinblastine regimen.  Cancer Treat Rep 70:1121,1986-1122,"},{"key":"R6-0188","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199008000-00010"},{"key":"R7-0188","doi-asserted-by":"crossref","unstructured":"Laubenstein  LJ,  Kriegel  RL,  Odajnyk  CM, et al:  Treatment of epidemic Kaposi\u2019s sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine.  J Clin Oncol 2:1114,1984-1118,","DOI":"10.1200\/JCO.1984.2.10.1115"},{"key":"R8-0188","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80081-V"},{"key":"R9-0188","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92654-2"},{"key":"R10-0188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1112"},{"key":"R11-0188","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199701010-00007"},{"key":"R12-0188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2353"},{"key":"R13-0188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.653"},{"key":"R14-0188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2445"},{"key":"R15-0188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.683"},{"key":"R16-0188","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059101"},{"key":"R17-0188","unstructured":"Fellons  A,  Ohayon  R,  Vacassin  T, et al:  Biochemical effects of Navelbine on tubulin and associated proteins.  Semin Oncol 16:9,1989-14,"},{"key":"R18-0188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.9.1745"},{"key":"R19-0188","unstructured":"Hohneker  JA:  A summary of vinorelbine (Navelbine) safety data from North America Clinical Trials.  Semin Oncol 21:42,1994-47,   (suppl 10)"},{"key":"R20-0188","doi-asserted-by":"crossref","unstructured":"Errante  D,  Fasan  M,  Rizzardini  G, et al:  Evidence of activity of vinorelbine in patients with previously treated AIDS-associated Kaposi\u2019s sarcoma.  AIDS 10:1472,1996-1473,","DOI":"10.1097\/00002030-199612000-00024"},{"key":"R21-0188","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1201"},{"key":"R22-0188","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R23-0188","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R24-0188","unstructured":"Mantel  N:  Evaluation of survival data and two new rank order statistics arising in its consideration.  Cancer Chemother Rep 50:163,1966-170,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.7.1550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:39:56Z","timestamp":1653514796000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.7.1550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2000,4,7]]}},"alternative-id":["10.1200\/JCO.2000.18.7.1550"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.7.1550","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,4,7]]}}}